Edition:
United Kingdom

ProQR Therapeutics NV (PRQR.OQ)

PRQR.OQ on NASDAQ Stock Exchange Global Market

19.25USD
19 Oct 2018
Change (% chg)

$0.40 (+2.12%)
Prev Close
$18.85
Open
$18.88
Day's High
$19.69
Day's Low
$18.82
Volume
58,676
Avg. Vol
63,142
52-wk High
$22.85
52-wk Low
$2.78

Chart for

About

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates... (more)

Overall

Beta: --
Market Cap(Mil.): $112.31
Shares Outstanding(Mil.): 24.11
Dividend: --
Yield (%): --

Financials

  PRQR.OQ Industry Sector
P/E (TTM): -- 85.41 33.64
EPS (TTM): -2.03 -- --
ROI: -68.51 0.21 14.27
ROE: -75.74 1.17 15.99

ProQR soars as childhood blindness drug succeeds in early trial

Shares of ProQR Therapeutics NV surged 70 percent in premarket trading on Tuesday after an interim analysis of an early-stage trial showed that its experimental treatment for a rare form of childhood blindness improved vision.

05 Sep 2018

UPDATE 1-ProQR soars as childhood blindness drug succeeds in early trial

Sept 5 Shares of ProQR Therapeutics NV surged 70 percent in premarket trading on Tuesday after an interim analysis of an early-stage trial showed that its experimental treatment for a rare form of childhood blindness improved vision.

05 Sep 2018

ProQR drug for rare childhood blindness succeeds in early trial

Sept 5 Dutch drug developer ProQR Therapeutics NV said on Tuesday its interim analysis showed that an early-stage trial of an experimental treatment for a rare form of childhood blindness was successful in improving vision.

05 Sep 2018

BRIEF-ProQR Announces Q1 Loss Per Share Eur 0.34

* AT MARCH 31, 2018, PROQR HELD CASH AND CASH EQUIVALENTS OF €38.0 MILLION, COMPARED TO €48.1 MILLION AT DECEMBER 31, 2017 Source text for Eikon: Further company coverage:

09 May 2018

BRIEF-ProQR Provides Enrollment Update On QR-110 Clinical Trial

* PROQR PROVIDES ENROLLMENT UPDATE ON QR-110 CLINICAL TRIAL AND HIGHLIGHTS OPHTHALMOLOGY PRESENTATIONS AT ARVO

23 Apr 2018

Earnings vs. Estimates